Media release

DKSH Has Successfully Entered Into a Strategic Partnership With SciGen in Vietnam

DKSH Has Successfully Entered Into a Strategic Partnership With SciGen in Vietnam

DKSH has signed a strategic partnership with SciGen, a rapidly growing biopharmaceutical company, to supply Zometa® to the Vietnamese market. Once imported, the products will be distributed by local partners in Vietnam.

Ho Chi Minh City, July 21, 2023 – DKSH, a leading Market Expansion Services provider, has successfully entered into a strategic partnership with SciGen for the supply of Zometa®, a lifesaving oncology medicine, to Vietnam. By way of this partnership, SciGen’s Zometa® will be made available to a wider population base in Vietnam utilizing DKSH’s strong market expansion and commercialization capabilities. The products will be distributed by local distributors engaged by DKSH.

SciGen is a rapidly growing biopharmaceutical company that markets and commercializes innovative and affordable healthcare products worldwide. The company leverage commercialization and networking capabilities to in-licenses and distribute branded pharmaceutical products and medical devices to treat endocrinological and oncological diseases, and continuously fill and improve their pipeline and product portfolio. With its well-established footprint in Vietnam, the strategic partnership with DKSH plays an important part in SciGen’s plan to expand to this potential market with Zometa® (Zoledronic acid), a bone-targeted agent for skeletal complications in advanced cancers and multiple myeloma. The product is manufactured at state-of-the art manufacturing facilities in Europe.

Dr. Shazli Ahmed Khan, SciGen’s Region Commercial Head for Asia Growth Markets, said: "SciGen is actively exploring expansion opportunities across the Asia region with an objective to enhance access to its portfolio for the people who need it the most. Vietnam is a key market in SciGen’s Asian footprint, and the organization is committed to partnering with local healthcare organizations to achieve this objective for the benefit of Vietnamese patients. July 5, 2023, marks a milestone for SciGen and DKSH’s partnership journey to help Oncology patients together in Vietnam. At the forefront of this partnership remains a commitment to provide high-quality medicines and healthcare solutions to patients in Vietnam."

Phillip Wray, General Director, DKSH Pharma Vietnam, stated: "We are delighted to be a trusted partner to SciGen in expanding its business in Vietnam. By utilizing our global experience and local understanding, as well as collaboration with local distributors, we will share the same vision to improve accessibility of the high-quality oncology drug, Zometa®, across Vietnam."